d-aspartic acid has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagetta, V; Bonito-Oliva, A; Calabresi, P; Carta, M; Di Luca, M; Errico, F; Fisone, G; Gardoni, F; Marinucci, S; Napolitano, F; Picconi, B; Romano, R; Usiello, A; Vitucci, D; Zianni, E | 1 |
| Bachani, M; Johnson, TP; Lee, MH; Malik, N; Nath, A; Ruffin, A; Steiner, JP; Toodle, V; Vivekanandhan, S; Wang, T | 1 |
2 other study(ies) available for d-aspartic acid and oxidopamine
| Article | Year |
|---|---|
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic Acid; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synapses | 2011 |
Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor.
Topics: Animals; Antifungal Agents; D-Aspartic Acid; Fluconazole; Insulins; Neurodegenerative Diseases; Neuroprotection; Neuroprotective Agents; Oxidopamine; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1 | 2022 |